MedMira Inc
XTSX:MIR

Watchlist Manager
MedMira Inc Logo
MedMira Inc
XTSX:MIR
Watchlist
Price: 0.06 CAD Market Closed
Market Cap: CA$45.5m

P/E

-12
Current
33%
Cheaper
vs 3-y average of -18

Price to Earnings (P/E) ratio shows how much investors pay for each dollar of a company`s earnings. It`s calculated by dividing the company`s market value by its total earnings.

P/E
-12
=
Market Cap
CA$42.1m
/
Net Income
CA$-3.5m

Price to Earnings (P/E) ratio shows how much investors pay for each dollar of a company`s earnings. It`s calculated by dividing the company`s market value by its total earnings.

P/E
-12
=
Market Cap
CA$42.1m
/
Net Income
CA$-3.5m

Valuation Scenarios

MedMira Inc is trading above its industry average

If P/E returns to its Industry Average (20.8), the stock would be worth CA$-0.1 (272% downside from current price).

Statistics
Positive Scenarios
0/2
Maximum Downside
-272%
Maximum Upside
No Upside Scenarios
Average Downside
263%
Scenario P/E Value Implied Price Upside/Downside
Current Multiple -12 CA$0.06
0%
Industry Average 20.8 CA$-0.1
-272%
Country Average 18.6 CA$-0.09
-255%

Forward P/E
Today’s price vs future net income

Not enough data available to calculate forward P/E

Market Distribution

Lower than 100% of companies in Canada
Percentile
0th
Based on 1 768 companies
0th percentile
-12
Low
0 — 14.2
Typical Range
14.2 — 29.3
High
29.3 —
Distribution Statistics
Canada
Min 0
30th Percentile 14.2
Median 18.6
70th Percentile 29.3
Max 19 628.5

MedMira Inc
Glance View

Market Cap
45.5m CAD
Industry
Health Care

MedMira, Inc. is a biotechnology company, which through its subsidiaries, engages in the research, development, manufacture, and commercialization of diagnostics and technology platforms. The company is headquartered in Halifax, Nova Scotia. The firm is engaged in the development and commercialization of rapid diagnostics and technology platforms. The MedMira Rapid Vertical Flow (RVF) Technology platform is the basis for the Company's line of rapid tests. Its technology platform detects multiple biomarkers specific to several diseases using a single cartridge. Its Multiplo line of rapid tests for human immunodeficiency virus (HIV), Hepatitis B and C, and syphilis uses the platforms capabilities to deliver approximately up to four test results using one test cartridge and one drop of specimen. The company also has a research product line that facilitates technology licensing, contract manufacturing, and regulatory consulting. The firm sells its rapid tests through a network of medical distributors and strategic business development partners to customers in all sectors of the healthcare industry, including laboratories, hospitals and point-of-care clinics, among others.

MIR Intrinsic Value
0.001 CAD
Overvaluation 98%
Intrinsic Value
Price CA$0.06
Get AI-powered insights for any company or topic.
Open AI Assistant

Intrinsic Value is all-important and is the only logical way to evaluate the relative attractiveness of investments and businesses.

Warren Buffett